1. Home
  2. PRME vs BKSY Comparison

PRME vs BKSY Comparison

Compare PRME & BKSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.54

Market Cap

536.4M

Sector

Health Care

ML Signal

HOLD

Logo BlackSky Technology Inc.

BKSY

BlackSky Technology Inc.

HOLD

Current Price

$48.41

Market Cap

726.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRME
BKSY
Founded
2019
2013
Country
United States
United States
Employees
N/A
340
Industry
Medicinal Chemicals and Botanical Products
Radio And Television Broadcasting And Communications Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
536.4M
726.7M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
PRME
BKSY
Price
$3.54
$48.41
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$7.56
$28.50
AVG Volume (30 Days)
2.5M
2.3M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
18.18
N/A
EPS
N/A
N/A
Revenue
$4,632,000.00
N/A
Revenue This Year
$7.06
$27.03
Revenue Next Year
$47.01
$29.21
P/E Ratio
N/A
N/A
Revenue Growth
55.28
N/A
52 Week Low
$1.18
$10.61
52 Week High
$6.94
$52.88

Technical Indicators

Market Signals
Indicator
PRME
BKSY
Relative Strength Index (RSI) 59.16 61.33
Support Level $3.15 $17.36
Resistance Level $3.60 N/A
Average True Range (ATR) 0.23 4.50
MACD 0.07 0.62
Stochastic Oscillator 93.44 70.88

Price Performance

Historical Comparison
PRME
BKSY

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About BKSY BlackSky Technology Inc.

BlackSky Technology Inc is a provider of real-time geospatial intelligence. The company delivers on-demand, high-frequency imagery, monitoring, and analytics of some of the critical and strategic locations, economic assets, and events in the world. It designs, owns, and operates one of the industry's low earth orbit (LEO) small satellite constellations, optimized to capture imagery cost-efficiently where and when its customers need it. its Spectra AI software platform processes data from BlackSky's constellation and other third-party sensors to develop the critical insights and analytics that provide its customers with the actionable intelligence. Geographically, the company operates in North America, the Middle East, Asia, and Others.

Share on Social Networks: